PIV3
MCID: PRN029
MIFTS: 32

Parainfluenza Virus Type 3 (PIV3)

Categories: Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Parainfluenza Virus Type 3

MalaCards integrated aliases for Parainfluenza Virus Type 3:

Name: Parainfluenza Virus Type 3 20
Human Parainfluenza Virus Type 3 20
Piv3 20

Classifications:



Summaries for Parainfluenza Virus Type 3

GARD : 20 Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. There is currently no vaccine to protect against parainfluenza virus infections. Most HPIV infections resolve on their own and do not require special treatment, though medical intervention may be necessary for severe breathing problems. Most adults have antibodies against parainfluenza but can get repeat infections.

MalaCards based summary : Parainfluenza Virus Type 3, also known as human parainfluenza virus type 3, is related to viral pneumonia and respiratory syncytial virus infectious disease. An important gene associated with Parainfluenza Virus Type 3 is ZNF17 (Zinc Finger Protein 17), and among its related pathways/superpathways are Measles and NF-kappaB Signaling. The drugs Glutamic acid and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and monocytes.

Related Diseases for Parainfluenza Virus Type 3

Diseases related to Parainfluenza Virus Type 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 viral pneumonia 30.5 IFNB1 DDX58
2 respiratory syncytial virus infectious disease 30.3 NEU1 IFNB1
3 measles 30.3 IFNB1 IFNA1 DDX58
4 stomatitis 30.0 IFNB1 IFNA1 DDX58
5 venezuelan equine encephalitis 29.8 IFNB1 IFNA1
6 viral encephalitis 29.8 IFNB1 IFNA1
7 newcastle disease 29.8 NEU1 IFNB1 IFNA1 DDX58
8 mumps 29.6 IFNB1 IFNA1
9 influenza 29.5 NEU1 IFNB1 IFNA1 DDX58
10 herpes simplex 29.5 IFNB1 IFNA1 DDX58
11 swine influenza 29.3 NEU1 IFNB1 IFNA1 DDX58
12 fetal parainfluenza virus type 3 syndrome 11.4
13 bronchiolitis 10.7
14 vaccinia 10.6
15 polykaryocytosis inducer 10.4
16 croup 10.4
17 pneumonia 10.4
18 bronchopneumonia 10.3
19 meningitis 10.3
20 hydrocephalus 10.2
21 pertussis 10.2
22 diarrhea 10.2
23 lymphopenia 10.2
24 sting-associated vasculopathy with onset in infancy 10.1 IFNB1 DDX58
25 hantavirus pulmonary syndrome 10.1 IFNB1 DDX58
26 autoimmune disease 10.1
27 medulloblastoma 10.1
28 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
29 proteasome-associated autoinflammatory syndrome 1 10.1
30 legionnaire disease 10.1
31 severe cutaneous adverse reaction 10.1
32 aplastic anemia 10.1
33 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.1
34 deficiency anemia 10.1
35 chlamydia pneumonia 10.1
36 disease by infectious agent 10.1
37 erythema multiforme 10.1
38 bone disease 10.1
39 rapidly involuting congenital hemangioma 10.1
40 compensatory emphysema 10.1
41 parotitis 10.1
42 meningoencephalitis 10.1
43 mastitis 10.1
44 respiratory failure 10.1
45 chlamydia 10.1
46 allergic disease 10.1
47 aseptic meningitis 10.1
48 acute leukemia 10.1
49 guillain-barre syndrome 10.1
50 urethritis 10.1

Graphical network of the top 20 diseases related to Parainfluenza Virus Type 3:



Diseases related to Parainfluenza Virus Type 3

Symptoms & Phenotypes for Parainfluenza Virus Type 3

Drugs & Therapeutics for Parainfluenza Virus Type 3

Drugs for Parainfluenza Virus Type 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glutamic acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
2 Vaccines Phase 1, Phase 2
3 Immunologic Factors Phase 1
4 polysaccharide-K Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants Completed NCT00686075 Phase 1, Phase 2
2 An Expanded Phase1/2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Mos. of Age Terminated NCT00508651 Phase 1, Phase 2
3 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults Completed NCT03392389 Phase 1
4 Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein Completed NCT02564575 Phase 1
5 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children Completed NCT00345670 Phase 1
6 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age Completed NCT00493285 Phase 1
7 Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval Completed NCT01021397 Phase 1 rHPIV3cp45;rHPIV3cp45 placebo
8 Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval Completed NCT01254175 Phase 1
9 A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age Completed NCT00366782 Phase 1
10 Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age Completed NCT00308412 Phase 1
11 A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12-36 Months of Age With Serologic Evidence of Prior Exposure Recruiting NCT04144348 Phase 1
12 Phase 1 Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Active, not recruiting NCT03462004 Phase 1

Search NIH Clinical Center for Parainfluenza Virus Type 3

Genetic Tests for Parainfluenza Virus Type 3

Anatomical Context for Parainfluenza Virus Type 3

MalaCards organs/tissues related to Parainfluenza Virus Type 3:

40
Bone, Bone Marrow, Monocytes, Smooth Muscle, Endothelial, Fetal Lung

Publications for Parainfluenza Virus Type 3

Articles related to Parainfluenza Virus Type 3:

(show top 50) (show all 777)
# Title Authors PMID Year
1
Viral etiology and epidemiology of pediatric patients hospitalized for acute respiratory tract infections in Macao: a retrospective study from 2014 to 2017. 61
33771128 2021
2
Dynamics of nosocomial parainfluenza virus type 3 and influenza virus infections at a large German University Hospital between 2012 and 2019. 61
33253961 2021
3
Screening interferon antagonists from accessory proteins encoded by P gene for immune escape of Caprine parainfluenza virus 3. 61
33445054 2021
4
Phylogenetic and pathogenicity analysis of a novel lineage of caprine parainfluenza virus type 3. 61
33757898 2021
5
Evolution of the Seroprevalence of Pestivirus and Respiratory Viral Infections in Spanish Feedlot Lambs. 61
33445625 2021
6
A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. 61
33115876 2020
7
Viperin protein inhibits the replication of caprine parainfluenza virus type 3 (CPIV 3) by interaction with viral N protein. 61
32800881 2020
8
A spraying applicator device is not required for efficacy of a live intranasal respiratory vaccine in young calves, which improves user convenience. 61
33068827 2020
9
Sumoylation of Human Parainfluenza Virus Type 3 Phosphoprotein Correlates with A Reduction in Viral Replication. 61
33197004 2020
10
A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms. 61
32949635 2020
11
[Detection of respiratory pathogens and clinical features in 225 children with acute exacerbation of bronchial asthma]. 61
33172555 2020
12
Investigation of viral pathogens in cattle with bovine respiratory disease complex in Inner Mongolia, China. 61
33157218 2020
13
Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. 61
32661315 2020
14
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. 61
33097791 2020
15
Epidemiological characteristics of respiratory viruses in patients with acute respiratory infections during 2009-2018 in southern China. 61
32562851 2020
16
Phylogenetic and antigenic analysis of bovine parainfluenza virus type 3 isolated in Japan between 2002 and 2019. 61
32768220 2020
17
Exosomes promote caprine parainfluenza virus type 3 infection by inhibiting autophagy. 61
32427096 2020
18
Mycoplasma bovis and viral agents associated with the development of bovine respiratory disease in adult dairy cows. 61
31232526 2020
19
A Versatile Platform to Incorporate Viral Trimeric Antigens into Self-Assembling Nanoparticle Immunogens. 61
32676596 2020
20
Detection of bovine viral diarrhea virus genotype 1 in aerosol by a real time RT-PCR assay. 61
32295612 2020
21
Beta-catenin inhibits bovine parainfluenza virus type 3 replication via innate immunity pathway. 61
32127006 2020
22
Evaluation of novel multiplex qPCR assays for diagnosis of pathogens associated with the bovine respiratory disease complex. 61
32113583 2020
23
Interferon-stimulated genes inhibit caprine parainfluenza virus type 3 replication in Madin-Darby bovine kidney cells. 61
31928705 2020
24
Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy. 61
32047132 2020
25
An investigation into respiratory tract viruses in children with acute lower respiratory tract infection or wheezing. 61
27854115 2020
26
The DI-DII linker of human parainfluenza virus type 3 fusion protein is critical for the virus. 61
31768710 2020
27
RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X. 61
31936642 2020
28
Emerging views of mitophagy in immunity and autoimmune diseases. 61
30951392 2020
29
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. 61
32045432 2020
30
Bta-miR-98 Suppresses Replication of Caprine Parainfluenza Virus Type 3 Through Inhibiting Apoptosis by Targeting Caspase-3. 61
32983081 2020
31
Identification of the Functional Domain of HPIV3 Matrix Protein Interacting with Nucleocapsid Protein. 61
33457403 2020
32
Increased Detection of Viruses in Children with Respiratory Tract Infection Using PCR. 61
31952364 2020
33
Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. 61
31541573 2020
34
Mutations in the HRB linker of human parainfluenza virus type 3 fusion protein reveal its importance for fusion activity. 61
31628980 2020
35
Cholesterol 25-Hydroxylase inhibits bovine parainfluenza virus type 3 replication through enzyme activity-dependent and -independent ways. 61
31767082 2019
36
Antiviral activity of amides and carboxamides of quinolizidine alkaloid (-)-cytisine against human influenza virus A (H1N1) and parainfluenza virus type 3. 61
31790286 2019
37
Panther Fusion® Respiratory Virus Assays for the detection of influenza and other respiratory viruses. 61
31743836 2019
38
PI4KB on Inclusion Bodies Formed by ER Membrane Remodeling Facilitates Replication of Human Parainfluenza Virus Type 3. 61
31747597 2019
39
Molecular epidemiology of an outbreak of human parainfluenza virus 3 among oncology patients. 61
31356855 2019
40
Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells. 61
31022559 2019
41
The novel caprine parainfluenza virus type 3 showed pathogenicity in Guinea pigs. 61
31163247 2019
42
Analysis of Paramyxovirus Transcription and Replication by High-Throughput Sequencing. 61
31189700 2019
43
Profiling of local disease-sparing responses to bovine respiratory syncytial virus in intranasally vaccinated and challenged calves. 61
31146050 2019
44
Respiratory virus associated with surgery in children patients. 61
31208426 2019
45
[Risk factors for calf mortality influence the occurrence of antibodies against the pathogens of enzootic bronchopneumonia]. 61
31212341 2019
46
Detecting respiratory viruses in children with protracted bacterial bronchitis. 61
31047118 2019
47
Virion-Associated Cholesterol Regulates the Infection of Human Parainfluenza Virus Type 3. 61
31096557 2019
48
Proteomics analysis reveals heat shock proteins involved in caprine parainfluenza virus type 3 infection. 61
31101113 2019
49
Isolation of a Divergent Strain of Bovine Parainfluenza Virus Type 3 (BPIV3) Infecting Cattle in China. 61
31146368 2019
50
Epidemiological investigation and phylogenetic analysis of caprine parainfluenza virus type 3 in sheep of China. 61
30770651 2019

Variations for Parainfluenza Virus Type 3

Expression for Parainfluenza Virus Type 3

Search GEO for disease gene expression data for Parainfluenza Virus Type 3.

Pathways for Parainfluenza Virus Type 3

Pathways related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.17 IFNB1 IFNA1 DDX58 CIITA
2 12.15 IFNA1 DDX58 CIITA
3
Show member pathways
12.11 IFNB1 IFNA1 DDX58
4
Show member pathways
12.08 IFNB1 IFNA1 DDX58
5 11.95 ZNF17 IFNB1 IFNA1 DDX58
6 11.69 IFNB1 IFNA1 CIITA
7
Show member pathways
11.42 IFNB1 IFNA1 DDX58 CIITA
8 11.04 IFNB1 IFNA1
9 10.89 IFNB1 CIITA

GO Terms for Parainfluenza Virus Type 3

Biological processes related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.54 IFNB1 IFNA1 DDX58
2 B cell differentiation GO:0030183 9.48 IFNB1 IFNA1
3 type I interferon signaling pathway GO:0060337 9.46 IFNB1 IFNA1
4 humoral immune response GO:0006959 9.43 IFNB1 IFNA1
5 B cell proliferation GO:0042100 9.4 IFNB1 IFNA1
6 T cell activation involved in immune response GO:0002286 9.32 IFNB1 IFNA1
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNB1 IFNA1
8 natural killer cell activation involved in immune response GO:0002323 9.16 IFNB1 IFNA1
9 response to exogenous dsRNA GO:0043330 9.13 IFNB1 IFNA1 DDX58
10 cellular response to exogenous dsRNA GO:0071360 8.8 IFNB1 DDX58 CIITA

Molecular functions related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 8.96 IFNB1 IFNA1
2 type I interferon receptor binding GO:0005132 8.62 IFNB1 IFNA1

Sources for Parainfluenza Virus Type 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....